Toronto Reports 523 Opioid Overdose Deaths Last Year
Toronto Reports 523 Opioid Overdose Deaths Last Year
Introduction
According to preliminary data from Toronto Public Health, there were 523 opioid toxicity deaths in the city in 2023, marking a 74% increase from 2019 when 301 deaths were recorded due to toxic drugs.
Of the 523 drug-related deaths in 2023, 427 have been classified as accidental. Almost half of these individuals were aged 25 to 44, with 54% living in private residences and 39% dying at home. The 2023 figures show a slight increase from 2022, which saw 510 deaths from unregulated drugs. Public Health Ontario and the Office of the Chief Coroner for Ontario confirmed 507 of those deaths, with three considered probable.
The peak of the pandemic in 2021 saw a record-breaking 591 confirmed drug toxicity deaths in Toronto. The city's Medical Officer of Health described the ongoing drug toxicity epidemic as a devastating human tragedy that necessitates a compassionate response. Toronto’s unregulated drug supply has become increasingly toxic, contaminated with unexpected and dangerous substances.
Toronto Public Health has issued four drug alerts this year to inform drug users, harm reduction organizations, and public health units about potent toxic substances in the unregulated drug supply and rising suspected overdoses.
One key response to this crisis is the implementation of supervised consumption services (SCS), which provide clinical spaces where individuals can use drugs under the supervision of trained health professionals. Toronto currently has ten such sites.
Evidence indicates that SCSs save lives, connect people to social services, and serve as pathways to treatment. Toronto Public Health advocates for greater access to a comprehensive range of evidence-based healthcare services, including prevention, treatment, and harm reduction supports. The health unit remains committed to exploring collaborative solutions to this urgent public health issue.
Latest News
Zimmer Biomet Gets FDA Approval for Cementless Partial Knee
Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…
Court Names Special Masters for Bard Mesh Claim Settlements
The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…